University of Texas Health Science Center at Houston

UTHealth joins trial of arthritis drug’s effect on COVID-19-induced cytokine storm

Newswise — A drug is being studied for its effectiveness in treating a type of severe immune overreaction seen in patients with COVID-19-induced pneumonia by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.

The Phase III, multisite, randomized, double-blind, placebo-controlled study is evaluating the effectiveness of the drug canakinumab, an interleukin-1 (IL-1) blocker approved for the treatment of juvenile rheumatoid arthritis, for preventing cytokine release syndrome (CRS) in COVID-19 patients with pneumonia.

Often referred to as a cytokine storm, CRS is a life-threatening immune reaction caused by the body releasing too many cytokines into the blood at once. Cytokines include a broad category of proteins secreted by the body. IL-1 serves as the first-line defense for the immune system, alerting other proteins to respond if a virus or bacteria are present.

Canakinumab blocks the production of IL-1 protein, which could prevent a possible deadly overreaction of the immune system in COVID-19 patients. Research has linked a number of COVID-19 deaths to CRS due to damage caused to several major organs.

The COVID-19 pandemic has reminded researchers at UTHealth of the early days of the HIV pandemic, when confusion and fear affected many communities and few treatment options were available.

Roberto C. Arduino, MD, the study’s lead investigator and professor of infectious disease with McGovern Medical School at UTHealth, said this is a time for the HIV research community to utilize members’ expertise in the search for a treatment for the coronavirus. Arduino’s research background includes the study of new antiretroviral drugs, treatment strategies, immune activation, and inflammation in the search of a HIV cure.

“The research community truly feels compelled to do something in the search for a viable treatment for COVID-19, and I feel I owe it to my community to offer my expertise,” said Arduino, who has led HIV clinical research for 22 years.

Researchers are investigating if canakinumab combined with standard-of-care treatment can increase the chances of survival without ever requiring invasive mechanical ventilation in patients with COVID-19-induced pneumonia. Over a two-hour period, patients who are enrolled will receive either a 450 mg, 600 mg, or a 750 mg IV dose of canakinumab based on their body weight; or placebo. All participants will be monitored for up to 29 days, or until they are discharged from the hospital. A follow-up will occur at 127 days.

Novartis Pharmaceuticals and the National Institutes of Health AIDS Clinical Trials Network are sponsoring this clinical trial. For more information, visit

Filters close

Showing results

110 of 3476
Newswise: UC San Diego Health Joins International Clinical Trial to Test Coronavirus Vaccine
Released: 1-Oct-2020 3:35 PM EDT
UC San Diego Health Joins International Clinical Trial to Test Coronavirus Vaccine
University of California San Diego Health

UC San Diego Health will be a test site for a third, major Phase III clinical trial to assess a vaccine candidate for the novel coronavirus that causes COVID-19. Sponsored by Janssen Pharmaceuticals, the trial will recruit up to 60,000 participants at sites in the United States and worldwide.

Released: 1-Oct-2020 2:50 PM EDT
UC San Diego Partners with San Ysidro Health to Expand COVID-19 Testing
University of California San Diego Health

Researchers at University of California San Diego School of Medicine, in collaboration with local partners, have been awarded a $5 million grant from the National Institutes of Health (NIH) to implement a program of widespread testing for COVID-19 in San Ysidro, focused on pregnant women and children.

Newswise: Promising COVID-19 Rapid Test Technology Enters Phase 1 of NIH Challenge
Released: 1-Oct-2020 2:25 PM EDT
Promising COVID-19 Rapid Test Technology Enters Phase 1 of NIH Challenge
Columbia University School of Engineering and Applied Science

A promising new COVID-19 rapid-testing technology platform developed by Rover Diagnostics and Columbia Engineering has been selected by the NIH to enter Phase 1 of the RADx initiative to support new COVID-19 testing technologies. The affordable, portable, and ultrafast point-of-care Rover platform provides reverse transcription polymerase chain reaction results in eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests.

30-Sep-2020 10:30 AM EDT
Researchers call for loss of smell to be recognized globally as a symptom of COVID-19

Four out of five people experiencing the recent loss of smell and/or taste tested positive for COVID-19 antibodies—and of those who tested positive, 40 percent did not have cough or fever, reports a new study in PLOS Medicine by Prof. Rachel Batterham at University College London and colleagues.

Released: 1-Oct-2020 1:35 PM EDT
COVID vs. Flu vs. Common Cold: What You Need to Know
Children's Hospital Los Angeles

With cold and flu season underway, plus the ongoing COVID-19 pandemic, infectious disease specialist Jeffrey Bender, MD, shares how to tell the difference between the three illnesses, and the most important thing parents can do to keep children safe.

Newswise: Carter-Butts-768x615.png
Released: 1-Oct-2020 1:20 PM EDT
Population distribution can greatly impact COVID-19 spread, UCI-led study finds
University of California, Irvine

Irvine, Calif., Oct. 1, 2020 — Uneven population distribution can significantly impact the severity and timing of COVID-19 infections within a city or county, leading individual communities to have vastly different experiences with the pandemic, according to a recent study led by the University of California, Irvine. Findings published in Proceedings of the National Academy of Sciences show that the heterogeneous spatial features of interpersonal connections may produce dramatic local variations in exposures to those with the illness.

Released: 1-Oct-2020 1:15 PM EDT
Arizona State University researchers awarded $4.7M by NIH to expand COVID-19 testing in underserved Arizona communities
Arizona State University (ASU)

In Arizona, as in other parts of the country, data shows that COVID-19 has disproportionately affected the American Indian, African American and Latinx communities, as well as other vulnerable populations. A $4.7 million grant from the National Institute of Health to ASU’s Southwest Interdisciplinary Research Center (SIRC) is on the way to help address this by funding a rapid and large-scale increase in COVID-19 testing of underserved communities across Arizona.

Newswise: 244645_web.jpg
Released: 1-Oct-2020 12:55 PM EDT
High risk of deep vein thrombosis and pulmonary embolism in patients with COVID-19
Medical University of Vienna (MedUni Wien)

In a systematic review of the worldwide published data on "Venous thromboembolism (VTE) in COVID-19 patients", Cihan Ay, Stephan Nopp, and Florian Moik from the Department of Medicine I, Clinical Division of Haematology and Haemostaseology, now for the first time, provide an in-depth analysis on the risk of VTE in patients hospitalised for COVID-19.

access_time Embargo lifts in 2 days
Embargo will expire: 1-Oct-2020 4:00 PM EDT Released to reporters: 1-Oct-2020 10:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 1-Oct-2020 4:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Showing results

110 of 3476